567 related articles for article (PubMed ID: 31654558)
1. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale.
Gevorgyan Fleming R; Kumar P; West B; Noureddin N; Rusheen J; Aboulhosn J; Tobis JM
Catheter Cardiovasc Interv; 2020 Feb; 95(3):365-372. PubMed ID: 31654558
[TBL] [Abstract][Full Text] [Related]
2. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
[TBL] [Abstract][Full Text] [Related]
3. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
4. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
Aral M; Mullen M
Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
[TBL] [Abstract][Full Text] [Related]
5. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
[TBL] [Abstract][Full Text] [Related]
6. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
Moon J; Kim M; Oh PC; Shin DH; Park HM; Jo YY; Lee JS; Kang WC
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):347-353. PubMed ID: 30396838
[TBL] [Abstract][Full Text] [Related]
7. Long-term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders.
Suligoj NC; Rojko M; Suligoj B; Zorc M; Kar S; Noc M
Catheter Cardiovasc Interv; 2020 Feb; 95(3):349-354. PubMed ID: 31131978
[TBL] [Abstract][Full Text] [Related]
8. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device.
Varotto L; Bregolin G; Paccanaro M; De Boni A; Bonanno C; Perini F
Cerebrovasc Dis; 2020; 49(2):124-134. PubMed ID: 32289794
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
[TBL] [Abstract][Full Text] [Related]
10. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
[TBL] [Abstract][Full Text] [Related]
11. Management of residual shunts after initial percutaneous patent foramen ovale closure: a single center experience with immediate and long-term follow-up.
Diaz T; Cubeddu RJ; Rengifo-Moreno PA; Cruz-Gonzalez I; Solis-Martin J; Buonanno FS; Inglessis I; Palacios IF
Catheter Cardiovasc Interv; 2010 Jul; 76(1):145-50. PubMed ID: 20578100
[TBL] [Abstract][Full Text] [Related]
12. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
[TBL] [Abstract][Full Text] [Related]
13. Recurrent cerebrovascular events in patients after percutaneous closure of patent foramen ovale.
Karagianni A; Mandalenakis Z; Dellborg M; Mirzada N; Johansson MC; Eriksson P
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104860. PubMed ID: 32430239
[TBL] [Abstract][Full Text] [Related]
14. Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal Occluder device and Amplatzer PFO Occluder device 30/35).
Giordano M; Gaio G; Santoro G; Palladino MT; Sarubbi B; Golino P; Russo MG
Int J Cardiol; 2019 Mar; 279():47-50. PubMed ID: 30344060
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous patent foramen ovale closure using Helex and Amplatzer devices without intraprocedural echocardiographic guidance.
Siddiqui IF; Michaels AD
J Interv Cardiol; 2011 Jun; 24(3):271-7. PubMed ID: 21114532
[TBL] [Abstract][Full Text] [Related]
16. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
[TBL] [Abstract][Full Text] [Related]
17. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
[TBL] [Abstract][Full Text] [Related]
18. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
[TBL] [Abstract][Full Text] [Related]
19. Single centre experience with GORE-HELEX septal occluder for closure of PFO.
Ponnuthurai FA; van Gaal WJ; Burchell A; Mitchell A; Wilson N; Ormerod O
Heart Lung Circ; 2009 Apr; 18(2):140-2. PubMed ID: 18294910
[TBL] [Abstract][Full Text] [Related]
20. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
